The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.
The post discusses the user's hair loss treatment involving daily use of 5% minoxidil, rosemary oil 2-3 times a week, derma-rolling twice a week, and daily vitamin D. A reply suggests the user to start using finasteride before hair falls out.
A user is experimenting with applying undiluted peppermint oil to their scalp daily to stimulate hair growth, based on a rat study where peppermint oil outperformed minoxidil. The user reports immediate hair thickening and increased scalp blood flow, while others in the conversation express skepticism, humor, and concern about the undiluted application.
A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.
The conversation is about the potential benefits of Rapamycin for hair pigmentation and regeneration, based on effects observed in mice. The original poster is seeking personal experiences from others using Rapamycin for longevity.
Exploring the potential of using verteporfin during hair transplants to minimize scarring and regenerate follicles, as well as discussing a possible standardized protocol for this treatment.
User shares 3.5-month hair transformation using 0.5 mg Dutasteride daily and Minoxidil 2x daily. Others express amazement and discuss safety profiles of treatments.
Naepo's 5-month progress report detailing their journey of treating male pattern baldness with dutasteride and oral minoxidil, which has already resulted in an encouraging improvement in hair density. Others have responded with appreciation for the thorough report and asked further questions about Naepo's educational background.
L'Oreal is working on hair cloning, with multiple companies using similar techniques, making hair cloning likely by 2030. The conversation expresses optimism about the progress and potential affordability of hair cloning solutions.
The conversation discusses a new study on topical pumpkin seed oil for hair loss in mice. Treatments mentioned include Minoxidil, finasteride, and RU58841.
Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
The user used Minoxidil 5% for 18 months, seeing improved hair density but no change in the crown area. They are cautious about using Finasteride again due to past gynecomastia.
Ketoconazole shampoo is primarily for scalp health and reducing inflammation, not hair regrowth. Combining ketoconazole with finasteride can yield similar results to using minoxidil and finasteride together.
Tristan Tate's hair loss is discussed, with mentions of finasteride, minoxidil, and dutasteride as treatments. Users speculate on his hair styling, steroid use, and legal troubles.
Scientists discovered a sugar gel, 2dDR-SA, that increased hair growth in mice. Users discussed its potential, comparing it to other treatments like Minoxidil and finasteride.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
A user shared progress pictures showing improvement from NW6 diffuse to NW1 after 5 months of finasteride and 2 months of dutasteride. Another user asked if these treatments affected beard or body hair thickness.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and future hopes for hair cloning. Users express skepticism and frustration over current and future solutions.
User experienced hair thinning due to high cortisol and thyroid issues, along with insulin resistance. They are taking magnesium, zinc, vitamin D, calcium, and selenium as supplements.
The user experienced reduced hairfall after taking multivitamins, biotin pills, eating fruit, and drinking coffee. They are concerned about the lack of hair regrowth and seek advice on whether their hair will be alright.
People discussed their experiences with anti-androgens for hair loss, mentioning side effects like chest pains with RU58841 and skepticism due to lack of safety data, while considering Fluridil as a potential addition to treatment. Some users expressed reluctance to use these chemicals.
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
Stemson Therapeutics announced a breakthrough in hair growth technology using stem cells. Users discussed the potential high cost and skepticism about the treatment's accessibility.
The user emphasizes hydration, androgen receptors, and a 7-day ejaculation recovery period for appearance enhancement. They suggest Minoxidil, finasteride, and RU58841 for hair loss, along with a diet rich in animal fats, specific exercises, and fasting.
Topical melatonin may have positive effects on hair loss by keeping hair in the growing phase. Users are discussing product recommendations and DIY methods for incorporating melatonin into their hair care routine.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.